Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study.
María Isabel López GálvezLluís Arias BarquetMarta S FigueroaAlfredo García-LayanaJosé M Ruiz Morenonull nullPublished in: Acta ophthalmologica (2020)
At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naïve nAMD.